EVMN Evommune, Inc.
P/E
--
Forward P/E
--
Price/Sales
18.51
Beta
--
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Evommune Announces Exclusive Licensing Agreement for Immunology Drug Candidate EVO570
Evommune, Inc. announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. for the drug candidate EVO570. The agreement...
Evommune In-Licenses VAV1 Degrader, Secures $30M in Concurrent Private Placement
Evommune entered into an exclusive licensing agreement with Hinova Pharmaceuticals for its VAV1 degraders, including the lead compound EVO570, for all...